Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Mar 17;11(3):60.
doi: 10.1038/s41408-021-00453-z.

Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study

Patrick K Reville  1 , Hagop M Kantarjian  2 , Farhad Ravandi  2 , Elias Jabbour  2 , Courtney D DiNardo  2 , Naval Daver  2 , Naveen Pemmaraju  2 , Maro Ohanian  2 , Yesid Alvarado  2 , Lianchun Xiao  3 , Gheath Alatrash  4 , Sanam Loghavi  5 , Caitlin R Rausch  6 , Gautam Borthakur  2 , Marina Konopleva  2 , Jorge Cortes  7 , Tapan M Kadia  8
Affiliations
Clinical Trial

Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study

Patrick K Reville et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

HMK: Consulting/honorarium: AbbVie, Actinium (Advisory Board), Agios, Amgen, Immunogen, Pfizer. Research Grants: AbbVie, Agios, Amgen, Ariad, Astex, BMS, Cyclacel, Daiichi-Sankyo, Immunogen, Jazz Pharma, Novartis, Pfizer. FR: Research funding and member of advisory boards from BMS. EJ: Research grants and consultancy from Abbvie, Adaptive biotechnology, Amgen, BMS, Genentech, Pfizer, and Takeda. CDD: Research grants (to institution): Abbvie, Agios, Calithera, Celgene, Daiichi-Sankyo. Consultant/Advisory Boards: Abbvie, Agios, Celgene, Daiichi Sankyo, ImmuneOnc, Novartis, Takeda, Notable Labs. ND: Consulting/honorarium: BMS, Novartis, Jazz, Daiichi-Sankyo, Astellas, Abbvie, Genentech, Immunogen, Trillium, Forty-Seven, Gilead, Syndax, Kite, Pfizer. Research grants: BMS, Pfizer, Abbvie, Genentech, Astellas, Daiichi-Sankyo, Immunogen, Novimmune, Trovagene, Amgen, Hanmi, Fate, Forty-Seven. NP: Consulting/honorarium: Celgene; Stemline; Incyte; Novartis; MustangBio; Roche Diagnostics, LFB, Pacylex, AbbVie; Research grants: Stemline; Novartis; AbbVie; Samus; Cellectis; Plexxikon; Daiichi-Sankyo; Affymetrix, SagerStrong Foundation. MK: Consulting/honorarium: AbbVie, Genentech, F. Hoffman La-Roche, Stemline Therapeutics, Amgen, Forty-Seven, Kisoji, Reata Pharmaceutical. Research grants: AbbVie, Genentech, F. Hoffman La-Roche, Stemline Therapeutics, Forty-Seven, Kisoji, Eli Lilly, Cellectis, Calithera, Ablynx, Agios, Ascentage, Astra Zeneca. JC: Consulting/honorarium: Novartis, Pfizer, BiopTah Holdings, Jazz, Takeda. Research grants: BMS, Novartis, Pfizer, Takeda, Jazz, Merus, Astellas, Amphivena, Celgene. TMK: Consulting/honorarium: Novartis, Abbvie, Genentech, Pfizer, JAZZ, Daiichi-Sankyo; Research grants: BMS, Celgene, Pfizer, Incyte, Genentech, Astra Zeneca, Amgen, Abbvie, JAZZ, Cellenkos, Cyclacel. P.K.R., M.O., Y.A., L.X., G.A., S.L., C.R.R., and G.B. all have no conflicts to disclose.

Figures

Fig. 1
Fig. 1. Survival and MRD Dynamics.
A Kaplan–Meier curve showing recurrence-free survival of the fifteen patients treated with maintenance nivolumab. B Kaplan–Meier curve showing overall survival of the fifteen patients treated with maintenance nivolumab. C Kaplan–Meier curve showing progression-free survival stratified by MRD status at study enrollment. D Kaplan–Meier curve overall survival stratified by MRD status at study enrollment. E Swimmer plot showing overall survival of nine patients with detectable MRD at enrollment along with one patient with undetectable MRD that relapsed. Black dot represents patient death while black arrow represents ongoing MRD negative CR. F MRD dynamics of the remaining seven patient with positive MRD at enrollment that did not clear MRD while on treatment with maintenance nivolumab. G MRD dynamics of patient #1 as measured by flow cytometry while on treatment with maintenance nivolumab. H MRD dynamics of patient #8 as measured by flow cytometry while on treatment with maintenance nivolumab.
See this image and copyright information in PMC

References

    1. Vasu S, et al. Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission. Blood Adv. 2018;2:1645–50. doi: 10.1182/bloodadvances.2017015222. - DOI - PMC - PubMed
    1. Rashidi A, Walter RB, Tallman MS, Appelbaum FR, DiPersio JF. Maintenance therapy in acute myeloid leukemia: an evidence-based review of randomized trials. Blood. 2016;128:763–73. doi: 10.1182/blood-2016-03-674127. - DOI - PMC - PubMed
    1. Wei AH, et al. Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission. N. Engl. J. Med. 2020;383:2526–37. doi: 10.1056/NEJMoa2004444. - DOI - PubMed
    1. Huls G, et al. Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients. Blood. 2019;133:1457–64. doi: 10.1182/blood-2018-10-879866. - DOI - PubMed
    1. Horowitz MM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555–62. doi: 10.1182/blood.V75.3.555.555. - DOI - PubMed

Publication types

Substances